Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) CFO Vaseem Mahboob sold 34,809 shares of the business’s stock in a transaction that occurred on Tuesday, October 27th. The stock was sold at an average price of $30.04, for a total transaction of $1,045,662.36. Following the completion of the sale, the chief financial officer owned 60,609 shares in the company, valued at $1,820,694.36. The trade was a 36.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Vaseem Mahboob also recently made the following trade(s):
- On Wednesday, October 28th, Vaseem Mahboob sold 39,903 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.48, for a total transaction of $1,216,243.44.
- On Thursday, October 29th, Vaseem Mahboob sold 4,788 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $30.60, for a total transaction of $146,512.80.
- On Friday, August 7th, Vaseem Mahboob sold 26,287 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $25.88, for a total value of $680,307.56.
- On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.68, for a total value of $172,636.60.
- On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.80, for a total value of $128,305.80.
- On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total value of $199,352.37.
Kestra Medical Technologies Stock Performance
Shares of NASDAQ KMTS opened at $29.69 on Friday. The company has a quick ratio of 4.69, a current ratio of 4.69 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $1.77 billion, a price-to-earnings ratio of -11.12 and a beta of 0.51. The stock’s fifty day simple moving average is $26.69 and its 200 day simple moving average is $23.82. Kestra Medical Technologies, Ltd. has a 52-week low of $17.34 and a 52-week high of $31.06.
Trending Headlines about Kestra Medical Technologies
Here are the key news stories impacting Kestra Medical Technologies this week:
- Positive Sentiment: Kestra will participate in upcoming investor conferences, which could improve visibility for its wearable cardiac-monitoring and defibrillation platform and give management an opportunity to discuss growth plans. Kestra Medical Technologies to Participate in Upcoming Investor Conferences
- Neutral Sentiment: Analyst sentiment remains generally constructive, with five Buy ratings, two Holds and one Sell rating. Evercore initiated coverage with an Outperform rating and a $34 price target, while the reported average target is $29. However, the company remains unprofitable, and its latest quarterly loss exceeded consensus expectations.
- Negative Sentiment: Insider selling is the clearest near-term negative catalyst. CFO Vaseem Mahboob sold 79,500 shares across October 27–29 for approximately $2.41 million, reducing his direct holdings to 60,609 shares. Director Traci Umberger separately sold 30,000 shares for about $900,900. The transactions may raise concerns about insider confidence or encourage profit-taking after KMTS’s strong advance. Kestra Medical Technologies Insider Selling
- Negative Sentiment: Fundamentals remain a risk: Kestra reported a quarterly loss of $0.75 per share versus the expected $0.61 loss, with a negative net margin and analysts projecting a full-year loss of approximately $2.45 per share.
Analyst Ratings Changes
KMTS has been the subject of a number of analyst reports. Weiss Ratings raised shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, September 16th. BTIG Research reissued a “buy” rating and issued a $32.00 target price on shares of Kestra Medical Technologies in a research report on Tuesday, September 15th. Piper Sandler restated an “overweight” rating on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research note on Saturday. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $29.00.
Get Our Latest Analysis on Kestra Medical Technologies
Institutional Investors Weigh In On Kestra Medical Technologies
Several hedge funds have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Kestra Medical Technologies during the 3rd quarter worth about $353,000. Sterling Capital Management LLC increased its holdings in shares of Kestra Medical Technologies by 834.0% in the 3rd quarter. Sterling Capital Management LLC now owns 878 shares of the company’s stock valued at $25,000 after purchasing an additional 784 shares during the period. Corient Private Wealth LP increased its holdings in shares of Kestra Medical Technologies by 284.2% in the 2nd quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after purchasing an additional 44,839 shares during the period. California State Teachers Retirement System lifted its position in shares of Kestra Medical Technologies by 39.2% in the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock worth $555,000 after purchasing an additional 7,844 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in shares of Kestra Medical Technologies by 6.6% in the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after purchasing an additional 5,731 shares in the last quarter.
About Kestra Medical Technologies
Kestra Medical Technologies, Inc is a medical technology company focused on developing and commercializing wearable solutions for patients at risk of sudden cardiac arrest. Its primary product is the ASSURE wearable cardioverter defibrillator, a wearable device designed to continuously monitor a patient’s heart rhythm and deliver a therapeutic shock when clinically necessary.
The company’s platform combines cardiac monitoring, arrhythmia detection and defibrillation capabilities in a wearable system intended for use outside the hospital.
Read More
- Five stocks we like better than Kestra Medical Technologies
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
